Charles Schwab Investment Management Inc. Has $9.83 Million Stake in Schrödinger, Inc. (NASDAQ:SDGR)

Charles Schwab Investment Management Inc. raised its position in Schrödinger, Inc. (NASDAQ:SDGR) by 2.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 509,680 shares of the company’s stock after purchasing an additional 11,167 shares during the period. Charles Schwab Investment Management Inc. owned 0.70% of Schrödinger worth $9,832,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. KBC Group NV increased its stake in shares of Schrödinger by 45.4% in the 3rd quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after acquiring an additional 783 shares in the last quarter. Paradigm Asset Management Co. LLC bought a new stake in shares of Schrödinger in the 4th quarter valued at $50,000. GAMMA Investing LLC increased its stake in shares of Schrödinger by 87.5% in the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock valued at $54,000 after acquiring an additional 1,305 shares in the last quarter. Quarry LP increased its stake in shares of Schrödinger by 1,150.0% in the 3rd quarter. Quarry LP now owns 2,825 shares of the company’s stock valued at $52,000 after acquiring an additional 2,599 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Schrödinger in the 3rd quarter valued at $102,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Price Performance

SDGR opened at $21.80 on Friday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -9.32 and a beta of 1.62. The firm’s fifty day moving average price is $22.92 and its two-hundred day moving average price is $20.77. Schrödinger, Inc. has a 1 year low of $16.67 and a 1 year high of $29.15.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $88.32 million for the quarter, compared to analysts’ expectations of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. As a group, equities analysts anticipate that Schrödinger, Inc. will post -2.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. KeyCorp boosted their price target on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.29.

Insiders Place Their Bets

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $21.76, for a total value of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at approximately $599,357.44. The trade was a 16.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.